Table 3.
Treatment‐emergent, treatment‐related adverse events in ≥3 patients
| N = 13 | Treatment‐emergent, treatment‐related adverse events | |
|---|---|---|
| All grades n (%) | Grade 3 n (%) | |
| Any adverse event | 9 (69.2) | 1 (7.7)a |
| Dysgeusia | 9 (69.2) | 0 |
| Muscle spasms | 5 (38.5) | 0 |
| Alopecia | 4 (30.8) | 0 |
| Decreased appetite | 4 (30.8) | 0 |
| Blood creatinine phosphokinase increased | 3 (23.1) | 0 |
| Constipation | 3 (23.1) | 0 |
| Diarrhea | 3 (23.1) | 0 |
No grade 4 or 5 treatment‐related adverse events were reported in this study.
a
One patient experienced grade 3 treatment‐related pyrexia.